![Jason O’Byrne](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason O’Byrne
Finanzdirektor/CFO bei
OLEMA PHARMACEUTICALS, INC.
Vermögen: 412 766 $ am 31.08.2026
Profil
Mr. Jason V.
O’Byrne is a Chief Financial & Accounting Officer at Olema Pharmaceuticals, Inc. Mr. O’Byrne was previously employed as a Chief Financial Officer & Executive Vice President by Vir Biotechnology, Inc., a Chief Financial & Accounting Officer by Caribou Biosciences, Inc., a Senior Vice President-Finance by Audentes Therapeutics, Inc., a Regional Controller by General Chemical Corp., and a Regional Head-Commercial Finance APAC by Genentech, Inc. He received his undergraduate degree from the University of British Columbia and an MBA from The Leonard N Stern School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VIR BIOTECHNOLOGY, INC. 0,02 % | 31.03.2026 | 37.730 ( 0,02 % ) | 412 766 $ | 31.08.2026 |
Aktive Positionen von Jason O’Byrne
| Unternehmen | Position | Beginn |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 11.08.2026 |
Ehemalige bekannte Positionen von Jason O’Byrne
| Unternehmen | Position | Ende |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Finanzdirektor/CFO | 03.08.2026 |
| CARIBOU BIOSCIENCES, INC. | Finanzdirektor/CFO | 27.09.2024 |
| AUDENTES THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.02.2021 |
General Chemical Corp.
 General Chemical Corp. Industrial SpecialtiesProcess Industries Manufactures and supplies metal lubricant products | Corporate Officer/Principal | 01.01.2005 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Ausbildung von Jason O’Byrne
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
66
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Caribou Biosciences, Inc.
 Caribou Biosciences, Inc. BiotechnologyHealth Technology Develops technology-based solutions for cellular engineering and analysis | Health Technology |
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
General Chemical Corp.
General Chemical Corp. Industrial SpecialtiesProcess Industries Manufactures and supplies metal lubricant products | Process Industries |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
The Leonard N Stern School of Business
 The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vir Biotechnology, Inc.
 Vir Biotechnology, Inc. BiotechnologyHealth Technology Develops cures and treatments drug for viral & bacterial diseases | Health Technology |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
